Zynex, Inc., a medical technology firm, announced Wednesday that it has received licensing approval from the state of Kentucky for its compound pharmacy business, Pharmazy.
This approval marks 42 states, plus the District of Colombia, in which Zynex is licensed to supply compound pharmacy services through Pharmazy.
"We are pleased with the expansion of our footprint for the compound pharmacy,” CEO of Zynex Thomas Sandgaard said. “We are continuing to work towards licensing in the remaining states."
Pharmazy is a community pharmacy that endeavors to meet the healthcare needs of each customer through offering pharmacist consultations, compounding prescription services, quality customer service and state-of-the-art automated prescription dispensing machines that guarantee quick and efficient service.
Zynex is an innovative medical technology company that specializes in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy. The company markets and sells its own design of electrotherapy medical devices.
In addition, Zynex also operates a non-sterile compound pharmacy that provides topical and transdermal pain cream. The company is currently developing a new blood volume monitor for use in surgery centers and hospitals.
“We began operating a non-sterile compound pharmacy and marketing our own proprietary 'Pharmazy' branded pain creams alongside electrotherapy products in 2014, to offer doctors a unique range of conservative pain management solutions,” Sandgaard said. "We are seeing a meaningful revenue contribution now from our compound pharmacy initiative and are encouraged by these results.”